Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bolt Biotherapeutics Inc.
Headquarters: Redwood City, CA, United States of America
Website: http://boltbio.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: William P. Quinn, MBA
Number Of Employees: 52
Enterprise Value: $-2,465,779
PE Ratio: -0.24
Exchange/Ticker 1: NASDAQ:BOLT
Exchange/Ticker 2: N/A
Latest Market Cap: $15,159,500
BioCentury | Feb 19, 2025
Deals
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report
Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more
BioCentury | May 22, 2024
Product Development
Clinical Report: GSK records asthma win
Plus: Data from Amgen-AstraZeneca, Biogen-Ionis and more
BioCentury | Feb 7, 2024
Product Development
Innate immunity gets another shot at cancer through ADCs
Immunostimulatory antibody-drug conjugates move from concept to clinical product
BioCentury | Dec 23, 2023
Discovery & Translation
Taking next-gen mAbs to new heights will lead modality innovation
Execs and investors weigh in on which technologies will yield the biggest gains in innovation in the near term and beyond: BioCentury survey
BioCentury | Aug 9, 2022
Deals
Mersana-GSK deal adds to immunostimulatory ADC momentum
The preclinical HER2-targeted ADC with a STING agonist payload is netting Mersana $100M up front and a path to co-commercialization
BioCentury | Mar 12, 2022
Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
BioCentury | Mar 5, 2022
Management Tracks
Entos builds out team with Chen as CMO, Ding as CBO
Plus Henderson becomes CEO of Wren, and updates from Bolt, argenx and more
BioCentury | Aug 27, 2021
Deals
Aug. 26 Quick Takes: Bolt, Innovent partner on non-traditional antibody conjugates
Plus ADC royalty deal, Sobi, Servier, DiCE IPO plans, AZ in Wilson’s and more
BioCentury | Jun 18, 2021
Deals
Genmab moves further away from ‘naked’ antibodies with mix-and-match modality deals
How the biologics company is thinking about combining modalities, and where it’s looking next
BioCentury | Jun 3, 2021
Deals
June 2 Quick Takes: Genmab, Bolt get bispecific; plus AbbVie, Transine, Sanofi, Puyi
Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and Bolt Biotherapeutics Inc. (NASDAQ:BOLT) partnered to discover and develop bispecific immune-stimulating antibody conjugates using Genmab’s antibodies and
Items per page:
1 - 10 of 21